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ABSTRACT 
Previous epidemiological studies have shown that colon cancer incidence is 
correlated to diet and estrogen status.  Phytoestrogens are molecules with similar 
structures to estrogen that occur naturally in plants. There is in vitro and in vivo evidence 
that phytoestrogens in the diet can inhibit carcinogenesis.  The phytoestrogenic 
mammalian lignans enterolactone (EL) and enterodiol (ED) in flaxseed have been shown 
to be effective in decreasing tumor incidence in carcinogenic models, but there is little 
data regarding their effects in non-malignant cells.  The following studies used a non-
transformed cell line of young adult mouse colonocytes (YAMC) to determine the 
protective effects of ED and EL in chemoprevention.  
Our results demonstrate that low levels of EL (1µM) and ED (5µM) are effective at 
significantly reducing cell growth and increasing apoptosis.  These treatments also 
regulated transcription via significant differences in gene levels related to apoptosis and 
cell cycle progression.  The data collected demonstrate some of the physiological effects 
of EL and ED on the cellular and molecular level.  These changes may contribute to the 
overall effect of prevention of colon cancer carcinogenesis seen with flaxseed 
consumption.  
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CHAPTER I 
INTRODUCTION 
Colorectal cancer is predicted to be the third most common cancer in both men 
and women in 2015 with over 90,000 new cases in the United States.1 Collectively, the 
literature shows a definitive link between estrogen receptors and colorectal 
carcinogenesis, and previous data from our laboratory has shown that estradiol (E2) 
alters normal colonocyte growth and is protective against the formation of preneoplastic 
lesions.2,3 These studies also revealed that the activity of E2 in the colon occurs primarily 
through estrogen receptor beta (ERβ).  Premenopausal women are less likely to develop 
colon cancer, and use of hormone replacement therapy (HRT) in postmenopausal 
women has been beneficial in reducing colon cancer risk. 4 Conversely, use of HRT 
post-menopause may also increase risk of breast cancer.  5 Because of this risk, dietary 
phytoestrogens have been targeted as a safer alternative for chemoprevention. 
Phytoestrogens, and consumption of them over time have been shown to inhibit 
carcinogenesis in in vitro, in vivo, and in epigenetic studies. 6-7 Flax (Linum 
usitatissimum) contains a high amount of phytoestrogens in the form of lignans.  Lignans 
are classified as non-flavonoid phytoestrogens and have been shown to have estrogenic 
effects. 8  The major lignan in flaxseed is secoisolariciresinoldiglucoside (SDG), along 
with other minor lignans including secosisolariciresinol and matairesinol. 9 When 
flaxseed is consumed by mammals, SDG is converted into enterodiol (ED) and 
enterolactone (EL) by gut bacteria. 10 Several in vitro and in vivo studies have 
demonstrated the anti-carcinogenic effects of flaxseed and its lignans.  In the 2006 study 
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by Bommareddy et al., Fischer rats were fed either corn meal or flaxseed meal 
supplemented diets for a week before a carcinogen was introduced. After 36 weeks, 
serum and the gastrointestinal tracts were collected and analyzed.  The rats fed flaxseed 
meal showed significantly decreased colon tumor incidence, average tumor number and 
size compared to rats fed corn meal diet. 11  In a similar study by the same author, 
ApcMin mice that were fed flaxseed supplemented diets showed significantly less tumor 
multiplicity and size in the colon and small intestine as compared to the corn 
supplemented control group.12 Bommareddy, Sung, and Danbara have all demonstrated 
inhibition of tumor cell growth by flax lignans EL and ED using human colon cancer 
cell lines. 13, 14, 15  
Currently, the in vivo research concerning ED and EL in colon carcinogenesis is 
exclusively presented in transformed carcinogenic cell models.  The present experiments 
were completed in non-transformed mouse colonocytes to better understand the 
protective mechanisms pre-carcinogenesis.  As colorectal cancer is predicted to be the 
third most prevalent cancer in the United States in the year 2015, the focus of anti-cancer 
research has shifted to prevention through lifestyle modifications. The lignans from 
flaxseed have been shown to be effective in preventing tumorigenesis in vivo, and could 
possibly offer a safer alternative to HRT in preventing colon cancer. 
We hypothesized that the flaxseed lignans EL and ED will decrease cell growth, 
and alter cell morphology of the colonocytes via modulation of transcription regulators.  
These effects will confer protection against the development of colon cancer.  To test our 
hypothesis we used a non-transformed young adult mouse colonocyte (YAMC) cell line.   
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CHAPTER II 
LITERATURE REVIEW 
Research Justification 
Colon Cancer 
  The colonic epithelium is constructed of crypts increasing the surface area 
available for absorption as well as separating the lumen from the lamina propria.  There 
are different types of cells organized in layers within the crypt.  Stem cells located at the 
base of the crypt proliferate rapidly differentiating into transit amplifying (TA) cells and 
eventually enterocytes; pushing existing cells up the crypt, and ultimately shedding them 
via apoptosis, or programmed cell death.16 Like most epithelial tissue, the sloughing off 
of dead cells near the luminal end of the colonic crypt is integral to the health of the 
tissue and is a tightly controlled process.  Apoptosis is mediated either extrinsically 
following binding of ligands to cell surface receptors or intrinsically from DNA damage 
or oxidative stress. In both cases the Caspase-3 protein is produced in the cell, signaling 
the final events of cell death.17  Carcinogenesis occurs when this cycle is disrupted and a 
polyp is formed in the crypt, which forms into an adenoma and eventually metastasizes. 
18 Originally, it was thought that cell proliferation was a critical marker for 
tumorigenesis; it is now accepted that apoptotic activity, specifically the inhibition of 
apoptosis, is an important indicator of tumor progression.19,20 
 Colon cancer is the second most common cause of cancer death, and is primarily 
seen in Caucasians with northern European heritage.  It is less commonly seen in those 
of Asian and African descent, but incidence rises with westernization and migration. 21  
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Generally, adult men are more likely to develop colon cancer at an earlier age than 
women, but the risk for women increases greatly after menopause when levels of 
endogenously produced estrogen drop dramatically.  
Estrogen 
Estrogens are cholesterol derived steroid hormones that are produced 
endogenously and are integral to homeostatic regulation in both males and females.  
Though typically linked to carcinogenesis in reproductive tissues, estrogen is also linked 
to other forms of cancer development in lung and gastrointestinal system tissues 
including the colon.  There are two different estrogen receptors (ER) in the body, alpha 
(ERα) and beta (ERβ). When activated, ERα promotes proliferation while ERβ generally 
induces anti-proliferative effects via apoptosis.22 The ERs are tissue specific with ERβ 
being the primary receptor in the colonic tissue.23  Because of ERβ’s prevalence in the 
colon, it has been implicated in the development and progression of colon cancer.  
Expression of ERβ in colon tissue is decreased with tumorigenesis and is inversely 
related to progression of colon cancer.24,25  Estrogen signaling in the colon has also been 
studied as an important mechanism in protecting against carcinogenesis in the colon.26 
 Previous studies from our laboratory have demonstrated treatment of non-
malignant cells with 17β-estradiol (E2) in vivo and in vitro increases apoptosis and 
decreases cell growth in a dose-responsive pattern.  This process is is mediated by ERβ.3  
Briefly, young adult mouse colonocyte (YAMCs) treated with 100-10,000pmol E2
exhibited a significant decrease in cell growth as well as a significant increase in 
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apoptosis measured by the caspase-3 protein. Female heterozygous estrogen receptor 
beta knockout (ERβ-KO) and wild type (WT) mice were utilized in the in vivo study to 
better understand the necessity of ERβ for estrogenic chemoprotection.  Mice were 
ovariectamized to prevent endogenous estrogen production and a cholesterol or 1nm 
estradiol pellet was inserted subcutaneously.  Azoxymethane (AOM), a chemical 
carcinogen, was injected and mice were sacrificed at eight weeks later.  At the time of 
sacrifice, blood and colonic tissue were resected and preserved for further analysis.  WT 
animals treated with E2 saw significantly fewer aberrant crypt foci (ACF), which are 
preneoplastic lesions indicative of carcinogenesis.  This effect was almost completely 
lost in the ERβ-KO mice, indicating the need of a functional ERβ for E2 to incur 
protective effects against colon cancer.  
Use of postmenopausal hormones has been shown to decrease the incidence of 
colon cancer in postmenopausal women by approximately 30-40%.27   Unfortunately, 
epidemiological evidence suggests that while lowering colon cancer risk, hormonal 
replacement therapy may also increase risk of developing breast cancer within five years 
of use.5 Due to this risk, interest in dietary compounds for the prevention of colon cancer 
has increased.  
Phytoestrogens 
  Phytoestrogens are naturally occurring compounds in plants that are structurally 
similar to the human hormone estradiol. These compounds have the ability to cause 
estrogenic or anti-estrogenic effects.  Types of phytoestrogens include isoflavones, 
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coumestanes, and phytoestrogen precursors called plant lignans which are transformed 
by the gut microbe of mammals into bioactive estrogenic mammalian lignans.  In Asian 
countries where diets are plant-based and high in phytochemicals, mortalities of breast, 
prostate, and colorectal cancer are lower than those in the western world where diets 
higher in animal proteins and saturated fats alter the production and function of steroid 
hormones.28 
In vivo studies from our laboratory suggest genistein (GEN), the primary 
phytoestrogen found in soybeans, has chemo-protective functions in the colon of mice.29 
Thirty mice were ovariectamized and either an E2 or cholesterol pellet was inserted 
subcutaneously at the base of the neck on the back.  One group of cholesterol treated 
mice were given a powdered GEN diet for 28 days before sacrifice and compared to 
mice treated with 1nm E2 or cholesterol alone.  Colon tissue was collected and the distal 
portion was sectioned and preserved in formaldehyde for analysis.  Using a TUNEL 
assay it was observed that colonic tissue from mice treated with E2 displayed a greater 
amount of apoptotic cells compared to the control.  Those mice fed the GEN diet also 
saw an increase in apoptosis, but not at the same level as E2.  This study not only 
demonstrated that E2 does induce the protective mechanism of apoptosis in the colonic 
crypt but that the phytoestrogen genistein may be beneficial in chemo-protection of the 
colon as well .  
Other phytoestrogens have also been effective chemo-protectants as evidenced in 
in vitro studies.  Phytoestrogens trigonelline (Trig) and diindolylmethane (DIM) have 
demonstrated regulation of YAMC cell growth via apoptosis and disruption of the cell 
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cycle.30  These effects were found to be mediated by ERβ, though neither compound 
bound directly to the receptor-binding pocket of the protein.  
Flaxseed 
 Flax (Linum usitassimum) is a flowering herb that belongs to the Lineaceae 
family. Native to West Asia and the Mediterranean, it has been grown and harvested 
since ancient times and is now cultivated around the globe with Canada, India, China, 
and Ethiopia being some of the largest exporters.31,32 Its seeds, also known as linseeds, 
are small and flat with a nutty taste.31 They have a seed coat called a testa, two embryos 
that make up most of the seed by weight, and a thin endosperm.33 The fiber from the flax 
plant can be used to create threads, twine and fabrics while the seeds are consumed for 
their oils.  When consumed flax is referred to as flaxseed while linseed is used to 
describe flax used in textiles and other industrial purposes.34 
Flaxseed is favorable for consumption due to its high levels of alpha-linolenic 
acid (ALA), fiber, and lignans, specifically SDG.  ALA is an essential omega-3 fatty 
acid that makes up over 50% of the lipid content in flaxseeds.35  Omega-3 fatty acids (ω-
3 FAs) are essential lipids that have been shown to be beneficial in the treatment and 
mitigation of several conditions.  Essential fatty acids are crucial to the normal 
functioning of cell membranes, organs like brain, kidney and liver, and are a key 
component of hormone functioning.  ω-3 FAs have also been shown to help prevent and 
mitigate chronic diseases such as cardiovascular disease, diabetes, obesity, metabolic 
syndrome, and gastrointestinal disorders.36  Studies also suggest ω-3 FAs may have anti-
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proliferative effects in cancer cells and may have the ability to improve the quality of life 
of cancer patients.37  The 2010 Guidelines for Healthy Americans recommend 
consuming at least 8 ounces of fish a week as a source for approximately 250mg of the ω-3 FAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).38  Flaxseed 
provides an alternative source of ω-3 FAs for those who cannot or choose not to eat fish, 
or who do not eat enough fish to meet this requirement.  
The fiber from flaxseeds also contributes health benefits.  Consuming dietary 
fiber can lower blood glucose levels by slowing gastric emptying and the release of 
sugar into the blood.39  Consuming high amounts of dietary fiber has also been shown to 
prevent weight gain in both men and women.40  There are approximately 25g of dietary 
fiber per 100g of flaxseed.41  The fiber in the seed is located in the outer layer known as 
the mucilage which has a high water-binding capacity.  This water-binding trait helps to 
alleviate and prevent constipation.39 
Flaxseeds also contain a high amount of phytoestrogens in the form of lignans.  
Lignans are classified as non-flavonoid phytoestrogens and have been shown to have 
estrogenic effects.8 Flaxseeds contain SDG, the major lignan, as well as minor amounts 
of the lignans secosisolariciresinol and matairesinol.9 When mammals consume plant 
lignans they are transformed by the gut microbes in the colon into bioactive compounds.  
It is believed that a group of microorganisms in the colon are responsible for the 
transformation of SDG to the mammalian lignans enterodiol (ED) and enterolactone 
(EL).  Wang et al. identified five different genetic bacterial lineages involved in this 
transformation via gel electrophoresis and named the consortium END-49.42  Clavel and 
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Woting were able to define the species responsible for transformation as Clostridium 
saccharogumia, Eggerthella lenta, Blautia producta, and Lactonifactor 
longoviformis43,44. Collectively these microorganisms are capable of converting SDG 
into EL and EL via secosisolariciresinol (Seco). 
Plasma levels of ED and EL in humans are inversely correlated with colon cancer 
incidence.  The Diet, Cancer and Health cohort conducted in Denmark followed over 
50,000 participants aged 50-64 for almost six years and a random selection of the cohort 
was selected for analysis of their plasma for EL levels.  For women, a higher 
concentration of EL in the plasma was associated with a lower risk for colon cancer.  
Interestingly, for men, an increase in plasma EL was associated with a higher risk of 
colon cancer.45  Kujisten et al. saw similar results with both lignans.  The researchers 
used data from the retrospective case-control POLIEP study conducted in the 
Netherlands.  Participants in the study were aged 18-75 with no history of inflammatory 
bowel disease or colon cancer. Each participant underwent an endoscopy, completed a 
questionnaire about their diet, medical history, and lifestyle, and gave a plasma sample.  
Participants with higher levels of both ED and EL in their plasma showed reduced risk 
of colorectal adenomas in a dose-dependent manner.46   
Several in vivo studies performed in mice and rats have shown similar protective 
effects.  One study compared flaxseed oil diets to those of corn oil and the effects on 
colon tumor development in Fischer rats.47  The carcinogen AOM was injected once a 
week for three weeks before the rats were sacrificed and blood and colonic tissue were 
collected.  There was 100% tumor incidence in the corn oil group as compared to only 
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54% in those fed flaxseed oil.  Tumor size and multiplicity were also significantly larger 
in the corn oil group when compared to the flaxseed oil group.  Bommareddy et al. 
conducted a similar experiment during which they fed their male Fischer rats either 
flaxseed or cornmeal diets, injected AOM, and collected blood and colon tissue 
samples.11  They also saw decreased tumor incidence in the flaxseed meal group.  Using 
western blots they discovered that the COX-1 and COX-2 proteins were significantly 
lowered in the colonic tissue of the flaxseed meal diet group. High levels of the COX 
protein in the cornmeal group may have propagated tumor formation because of the 
protein’s role in the conversion of arachidonic acid to prostaglandins which are known 
tumor promoters.  Another similar study compared flaxseed meal to flaxseed oil diets in 
chemoprevention.48  Fischer rats were fed either flaxseed meal or flaxseed oil and AOM 
was introduced at seven and eight weeks.  Both flaxseed oil and flaxseed meal were 
effective in reducing the incidence of ACF in both the proximal and distal colon.  These 
results were also confirmed in the ApcMin mouse model, which have point mutation in 
the Apc gene, leading to the development of polyps in the colon.  The results suggested 
that dietary flaxseed could protect against tumor formation, evidenced by significantly 
decreased tumor multiplicity in the mice fed flaxseed meal or oil.12  Hernandez-Salazar 
examined flaxseed’s influence on gene expression involved in colon carcinogenesis.49  
They fed Sprague-Dawley rats flaxseed and induced carcinogenesis via AOM injections.  
Those mice fed flaxseed diets had decreased crypt multiplicity of ACFs and modulated 
the expression of cell cycle arrest and apoptotic genes: p53, p21, bcl-2, bax, and 
caspase-3.   
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In order to better elucidate cellular mechanisms of flaxseed, several in vivo 
experiments were conducted.  Researchers used the Caco-2 cell line to model colon 
epithelial adenocarcinoma.  After treating cells with EL and ED, BrdU and propidium 
iodine staining were used to analyze proliferation and apoptosis respectively. Both EL 
and ED caused a significant increase in apoptotic cells and a decrease in proliferation.13  
Similar results were seen with EL in the Colo 201 human tumor cell line.15  So far, the 
majority of the in vitro research regarding the chemoprotective effects of EL an ED has 
been completed in transformed cell lines.  More research is needed to better understand 
the mechanisms of protection prior to carcinogenesis.   
Specific Aims 
 To determine the effect of flaxseed lignans (enterolactone) EL and (enterodiol) 
ED on cell growth, maintenance, and apoptosis in non-malignant colonocytes.  
Hypothesis 
 We predict: 
1. Non-malignant colonocytes treated with ED or EL will show similar
chemoprotective effects to those treated with E2.
2. Treated cells will show decreased growth and increased apoptosis via
transcriptional regulation.
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CHAPTER III 
CHEMOPROTECTIVE EFFECTS OF FLAXSEED LIGNANS ENTERODIOL AND 
ENTEROLACTONE IN NON-TRANSFORMED COLONOCYTES 
Introduction 
With colon cancer predicted to be the third most common cancer in 2015, there 
has been an increased research emphasis on prevention of colon cancer.1  Typically, pre-
menopausal women are less likely to develop colon cancer when compared to their post-
menopausal counterparts. The Women’s Health Initiative Study recognized that use of 
HRT in postmenopausal women was correlated to a significant decrease in the incidence 
of colon cancer.50  Estrogen’s chemoprotective mechanisms have been studied 
extensively, and previous studies from our laboratory have demonstrated these effects 
both in vivo and in vitro.3,26,29,30,2  
Recently, there has been an increased interest in the role of diet in cancer 
prevention.  Because colon cancer, and protection against colon cancers, is estrogen-
mediated, phytoestrogens have been studied as an alternative to HRT for 
chemoprevention.6,51  Common phytoestrogens found in plant based diets include GEN 
from soy and the mammalian lignans EL and ED that are formed when flaxseed is 
consumed by mammals and processed by the gut microbe.52  Previous research from our 
laboratory has proven the effectiveness of GEN, as well as other phytoestrogens like 
Trig and DIM, in chemoprotection of non-transformed colonocytes.29,30  
Research has shown that consumption of flaxseed is linked to lower risk of colon 
cancer development.53  Both in vitro and in vivo studies have provided possible 
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mechanisms of action, mainly mediated through the prominent ER in the colon, 
ERβ.13,24 The majority of the studies have focused on carcinogenesis models, with little 
to no emphasis on estrogenic effects pre-transformation.   
Our goal was to identify possible mechanisms by which the flaxseed lignans EL 
and ED may confer protection against the development of colon cancer, primarily 
through apoptosis and cell signaling pathways.  
Materials and Methods 
Reagents 
Enterodiol (ED) and enterolactone (EL) were purchased from Sigma-Aldrich. 
Reagents were dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich).  
Cells 
Young Adult Mouse Colonocytes (YAMC) were obtained from Dr. Harmut Land 
(University of Rochester Medical Center).  The cells are derived from the Immorto-
mouse and express the temperature-sensitive simian virus 40 large T under the control of 
an interferon-γ inducible promoter.  The cells were maintained in permissive conditions, 
33°C, 5% CO2 with 5 units interferon-γ (IFN-γ;	  Roche), and cultured in RPMI1640 
(Sigma Aldrich) with 10% fetal bovine serum (FBS; Hyclone), 0.1% insulin, transferrin, 
and selenious acid (ITS; BD Biosciences) and 1% gentamicin (GIBCO) on collagen 
coated plates.  For experiments cells were transferred to media containing 10% charcoal-
dextran stripped FBS, 0.1% ITS and 1% gentamicin 48 hours before conducting 
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experiment. During experiments, cells were placed at non-permissive conditions; 39°C, 
5% CO2.  
Cell Growth Assay 
  Cells were seeded at a concentration of 3.0 x 104 cells/well in 6-well collagen coated 
plates (Grenier bio-one), and grown at the permissive condition with IFN-γ	  for	  24	  hours.	  	  The	  cells	  were	  treated	  with	  ED	  or	  EL	  at	  concentrations	  of	  1,	  5,10	  μM,	  and	  100nM	  or	  0.1%	  DMSO	  and	  transferred	  to	  non-­‐permissive	  conditions	  for	  96	  hours.	  	  Media	  with	  treatments	  were	  replaced	  after	  48	  hours.	  	  After	  96	  hours,	  cells	  were	  trypsinized	  and	  collected	  for	  counting.	  	  Cell	  numbers	  were	  counted	  using	  a	  Cellometer	  Auto	  1000	  cell	  counter	  (Nexcelom).	  There	  were	  three	  wells	  per	  treatment,	  and	  each	  well	  was	  counted	  in	  triplicate.	  	  The	  experiment	  was	  replicated	  three	  times.	  	  
Caspase-3 Activity 
	  	  Cells were seeded and grown in same conditions as the cell growth assay.  Cells 
were treated for 96 hours with 1nM E2, 5μM ED, 1μM EL, and 0.1% DMSO. After 96 
hours of treatment, cells were trypsinized, collected and twice washed with PBS. 
Caspase-3 activity was measured according to the manufacturer’s protocol of EnzChek 
Caspase-3 assay kit #2, Z-DEVD-R110 substrate (Molecular Probes).  Cells were lysed 
and centrifuged, and supernatants transferred to a 96-well plate (BD Bioscience). 50μL 
of 2X working solution was added to each sample and incubated for 30 minutes in the 
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dark before reading. Fluorescence was measured with 496 (excitation)/ 520 (emission) 
nm at 15 minute intervals using a CLARIOstar microplate reader (BMG). 	  
Flow Cytometry 
Cells were seeded and grown in the same conditions and treatment as stated 
previously in the Caspase 3 assay.  Cells were trypsinized and collected, and the 
supernatant was removed.  After, they were washed with ice-cold 1X Phosphate Buffer 
Saline (PBS) and fixed overnight with 100% ethanol at -20°C. The cells were then 
stained with propidium iodide staining solution (50μg/ml propidiun iodide, 200μg/ml 
DNase-free Rnase, 5mM sodium citrate and 0.1% Trition X-100) at room temperature 
for 30 min.  Using an Accuri C6 flow cytometer (BD Bioscience), 2 x 104 live cells were 
analyzed for cell cycle distribution.  
RNA Extraction 
Cells were seeded at 10 x 104 cells/well in 6-well plates and grown at permissive 
conditions with IFN-γ for 24 hours.  The cells were then treated with 1nM E2, 5μM ED, 
1μM EL or 0.1% DMSO for 24 hours.  RNA was isolated using the manufacturer’s 
protocol for TRIzol Reagent (Invitrogen).  Cells were trypsinized and collected, then one 
mL TRIzol reagent was added to lyse the cell membrane. 200μL of chloroform was 
added and the aqueous phase was collected. 500μL isopropanol was added to precipitate 
the RNA, and the pellet was washed with 75% ethanol, air dried, then dissolved in 
Rnase-free water. Rnase were inactivated at 55-60°C and then stored at -70°C.   
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Real Time PCR 
The Transcriptor First Strand cDNA (Roche) synthesis kit was used to synthesize 
cDNA, and the manufacturer’s protocol was used.  1μg of RNA plus 1μL oligo dT 
primer and 2μL random Hexomer primer were incubated at 65°C for 10 minutes.  Next, 
4μL reaction buffer, 0.5	  μL Rnase inhibitor, 0.5	  μL reverse transcriptase, and 2 μL dNTP 
were added and incubated at 25°C for 10 minutes, 50°C for 60 minutes, and 85°C for 5 
minutes.  cDNA was stored at -20°C.  
Real time PCR was completed using the FastStart Universal SYBR Green Master mix 
(Roche).  The primers used and their sequences are as follows: Bcl-2 (Forward: ATC 
TTC TCC TTC CAG CCT GA, Reverse: TCA GTC ATC CAC AGG GCG AT), c-Myb 
(Forward: TGT CAA CAG AGA ACG GC TGA, Reverse: CAC AGA ACC ACA CTT 
GCA GC), c-Myc (Forward: GCC CSG TGA GGA TAT CTG GA, Reverse: ATC GCA 
GAT GAA GCT CTG G), Mdm2 (Forward: TGT CTG TGT CTA CCG AGG GTG, 
Reverse: TCC AAC GGA CTT TAA CAA CTT CA), CCND1 (Forward: GCG TAC 
CCT GAC ACC AAT CTC, Reverse: ACT TGA AGT AAG ATA CGG AGG GC), pS2 
(Forward: AGC ACA AGG TGA TCT GTG TCC, Reverse: GAA GCC AGA ATT TAT 
CCT CTC CC), and 18SRNA used as a control (Forward: TCA AGA ACG AAA GTC 
GA GGT, Reverse: GGA CAT CTA AGG GCA TCA CAG). Real time PCR was run on 
a Lightcycler® 480II (Roche) : 95°C  for 10 minutes, 45 cycles of 15 seconds at 95°C  
and 30 seconds at 60°C. 
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Statistical Analysis 
Each experiment was replicated in triplicate. The data is reported as the mean ± 
standard deviation (SD). Statistical significance was determined using JMP Pro 10 by a 
one way ANOVA, with p<0.05 considered significant.  
Results 
ED and EL Inhibit YAMC Cell Growth 
In order to determine the effects of ED and EL on cell growth in vitro, YAMCs 
were treated with 10µM, 5µM, 1µM, and 100n EL and ED separately, with 0.1% DMSO 
as the vehicle control. Cells treated with EL displayed a dose-dependent decrease in 
growth.  10µM and 5µM concentrations of EL and ED were significantly different 
(p<0.05) when compared to control (Fig 2).   
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A. 
B. 
Fig. 1: EL and ED inhibit growth of YAMC cells. Cells were grown in charcoal 
dextran-stripped media for 48 h prior to plating.  Cells were seeded at 30,000cells/well 
and grown at 39°C for 24 h prior to treatment.  Cells were treated with 10µM, 5µM, 
1µM, and 100nM EL, A and ED, B with 0.1% DMSO vehicle control for 96 h. Data are 
expressed as a percentage of the DMSO control group.  Mean (n=9) +/− SEM from three 
replicate experiments. Bars without a common letter differ, p <0.05.  
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Caspase-3 Activity in YAMC Cells Treated with ED and EL 
After observing a decrease in cell growth of YAMCs following treatment with ED 
and EL, the next step was to determine the level of apoptosis in those cells. Caspase-3 
activity was measured in cells treated with 1µM EL and 5µM ED with 0.1% DMSO as 
the vehicle control, and results were compared to the apoptotic activity of E2. 
Fluorescence measurements were taken at 30, 45, and 60 minutes.  The results suggest 
that there is a similar effect of caspase-3 activity in cells treated with ED and EL (Fig. 3) 
when compared to the positive control of E2.  
A. 
B. 
Fig. 2: Apoptosis in YAMCs treated with EL and ED. Cells were grown in charcoal dextran-stripped media for 48 h prior to 
plating.  Cells were seeded at 30,000 cells/well and grown in 39°C for 24 h prior to treatment.  Cells were treated with 5µM 
ED, 1µM EL, or 1nM E2, with 0.1% DMSO vehicle control for 96 h. Fluorescence was measured at A. 30 minutes, B 45 
minutes and C 60 minutes. Data are expressed as a percentage of the DMSO control group.  Mean (n=9) +/− SEM from three 
replicate experiments. Bars without a common letter differ, p <0.05.  
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C. 
Fig 2: Continued 
Cell Cycle Modulation by EL and ED 
Our next objective was to test whether EL and ED could modulate progression of 
the cell cycle.  The YAMCs were handled the same as the previous experiments and 
collected after 96 hours of treatment.  The cells were then fixed, stained and analyzed for 
cell cycle stage via flow cytometry (Fig. 4). There was not a significant difference 
between the treatments in regulation of cell cycle.  
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Fig. 3: Cell cycle modulation by EL and ED. Cells were grown in charcoal dextran-stripped media for 
48 h prior to plating.  Cells were seeded at 30,000 cells/well and grown in 39°C for 24 h prior to treatment. 
Cells were treated with 5µM ED, 1µM EL, or 1nM E2, with 0.1% DMSO vehicle control for 96 h.  Cells 
were fixed and stained with propidium iodine and then analyzed by a flow cytometer.  Mean (n=9) +/− 
SEM from three replicate experiments.  
Real Time PCR 
The final experiment was to test if EL and ED were transcriptional regulators.  Cells 
were seeded and treated with 5µM ED, 1µM EL, and 1nm E2, with 0.1% DMSO vehicle 
control for only 24 hours.  After cells were collected, RT-PCR was run with the gene 
targets Bcl-2, CCND1, Mdm2, and c-Myb, with 18s used for control (Fig. 5).  
Expression of Bcl-2 was significantly decreased by EL.  Mdm2 expression was only 
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significantly reduced by E2 treatment, and both EL and ED treatments were effective in 
significantly lowering expression of CCND1.  Levels of c-Myb were decreased slightly, 
but not significantly by treatment with E2, EL and ED.  
A. 
B. 
Fig. 4: Effect of EL and ED on gene expression. Cells were treated with 5µM ED, 
1µM EL, and 1nM E2, with a 0.1% DMSO control for 24 hours. Amplification was 
measured using SYBR green expression.  A. Bcl-2, B. CCND1, C. Mdm2, and D. c-
Myb. Gene expression was normalized by 18S. Values are mean (n=27) +/− SEM 
from three replicate experiments. Bars without a common letter differ, p <0.05. 
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C. 
D. 
Fig. 4: Continued 
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Discussion 
Flaxseed has been targeted for its many health benefits including its anti-
cancerous effects.  Though it contains other important nutrients, the mammalian lignans, 
EL and ED, formed by the gut microbe were of particular interest because of their 
phytoestrogenic properties.  Previous studies have shown these lignans to be effective in 
cancer treatment in vivo and in vitro, though none of the studies conducted focused on 
pre-malignant mechanisms for chemoprotection.11–13,15,47,48 Additionally, studies from 
our laboratory have shown estrogen and phytoestrogens to be protective against colon 
cancer development both in vivo and in vitro.3,29,30  The purpose of this study was to 
determine if flaxseed lignans were successful chemoprotective agents in non-
transformed colon epithelial cells, with a focus on regulation of cell cycle and apoptosis. 
The first step was to determine if treatment of the YAMCs with EL and ED was 
effective in reducing cell growth.  At 10µM and 5µM of EL and ED growth was reduced 
significantly up to 40% less than the control at the highest dosage.  We chose to chose to 
use 1µM and 5µM of EL and ED respectively because these doses reduced cell growth 
appropriately 20%, which was similar to the effects of E2 reported previously.3,29,30  In 
studies conducted in cancerous cell lines concentrations of EL and ED ranged from 50-
200µM.13,15 Because our experiments were conducted in non-transformed colonocytes, a 
much lower dose was chosen to prohibit cell growth from being reduced too drastically. 
Once appropriate levels of decreased growth were determined, the ability of these 
compounds to induce apoptosis was investigated.  Using the caspase-3 protein as a 
marker, a significant increase of apoptosis with E2, EL and ED treatment was seen. 
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These results indicate that increasing apoptosis may be a mechanism for the 
chemoprotective effect of EL and ED in colon carcinogenesis. Bommareddy et al. also 
demonstrated significant effects in apoptosis in Caco-2 cells, but the concentrations used 
ranged from 75-150µM.13  We demonstrated that significant apoptotic effects could be 
seen in non-transformed cells using considerably lower concentrations of treatment.  
The genes chosen for RT PCR analysis were known targets of estrogen 
regulation.  Bcl-2 was one of the first known regulators of apoptosis in mammals. High 
expression of the gene over long periods of time correlates with inhibition of apoptosis, 
allowing for tumor development.54  Therefore, down regulation of Bcl-2 in the colon 
epithelium permits programmed cell death to continue, decreasing the likelihood of 
adenoma formation.  Our results show a significant decrease in Bcl-2 expression when 
treated with 1µM EL. This was consistent with previously published results when even 
higher concentrations were used.15 The murine double minutes 2 oncoprotein or Mdm2 
has been shown to be a negative regulator of the p53 tumor suppressor, and is 
overexpressed in cancerous tissues including colonic adenomas.55 We did not find 
significant effects in cells treated with EL or ED.  A significant effect was seen with E2 
treatment, consistent with previously reported data.30  Increased expression of c-Myb is 
associated with colon cancers, and when heterozygously knocked down, survival has 
been shown to improve.56  In our experiments, c-Myb was not significantly reduced, but 
showed a decrease in all three treatment groups. Cyclin D1 (CCND1) is a tightly 
controlled cell cycle regulator, and disruption of its expression is common in cancer.57  
CCND1 accumulates in the cell during G1 and is degraded as the cell transitions into the 
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S phase. Overexpression of CCND1 has been shown to correlate to increased cancer 
risk.58  Our experiments showed that EL and ED significantly lowered expression of 
CCND1 after treatment, suggesting a potential mechanism for chemoprevention. 
Additionally, this result was interesting because CCND1 is integral to cell cycle 
progression, yet there were no significant differences seen in flow cytometry. In the 
cytometry experiments cells were treated for 96 hours, as opposed to only 24 hours in 
the RT PCR assay.  This leads us to believe that there may be other mechanisms 
involved in Ccnd1 expression past 24 hours.  
In conclusion, the compounds EL and ED reduced growth and increased 
apoptosis of YAMC cells.  There was also evidence of transcriptional regulation of 
apoptotic and cell cycle progression genes. Previously their effects had only been studied 
in carcinogenic cell lines or animal models, with much higher treatment doses. Our 
results lead us to believe that these effects are a component of the protective effect of 
flaxseed in the prevention of colon carcinogenesis.   
27 
CHAPTER IV 
SUMMARY AND CONCLUSIONS 
With almost 72,000 new cases of colon cancer expected for men, and close to 
66,000 for women in 2015, it has become imperative to identify mechanisms of 
chemoprotection.  The mammalian lignans EL and ED from flaxseed have been 
implicated in preventing the development of colon cancer.  These studies have been 
completed primarily in carcinogenic cell lines and animal models, with very little 
understanding of the effects these lignans have on non-transformed colonic tissue.  Our 
goal was to better elucidate these mechanisms.  Our first step was to test if EL and ED 
could depress YAMC cell growth.  Both EL and ED significantly reduced growth of the 
cells in a dose-responsive manner.  An appropriate concentration of the compounds was 
then chosen based on the percent decrease in cell growth.  1µM EL and 5µM ED each 
conferred around a 20% reduction in cell growth, which is similar to the effect seen 
when treated with physiological levels of estradiol.  The dosages were used throughout 
the rest of the experiments.  Out next step was to determine levels of apoptosis by 
measuring the amount of caspase-3 present in the cells after 96 hours of treatment.  EL 
and ED were able to significantly increase apoptosis, similar to E2, suggesting that 
apoptosis may be a contributing mechanism in chemoprotection via EL and ED.  After 
observing decreases in cell growth and increases in apoptosis, the question of whether 
EL and ED would cause significant changes in cell cycle progression was investigated.  
No significance was found between the treatments and control, but there were significant 
effects found when changes in gene expression were tested.  Real Time PCR was used to 
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determine the transcriptional modifications made by EL and ED in YAMCs.  Bcl-2 was 
lowered significantly by EL treatment, but not ED, and only E2 significantly reduced 
expression of Mdm2.  These results suggest that EL and ED treatment may regulate 
apoptosis through other avenues.  Interestingly, we did see some significance in genes 
related to cell cycle progression, despite not seeing any changes in the cell cycle assay.  
CCND1 was significantly reduced and c-Myb expression reduced, but not significantly.  
This data leads us to believe there may be some transcriptional regulation of the cell 
cycle by EL and ED.  The difference between the RT-PCR and cell cycle assays was 
time of treatment.  The cells used in RT-PCR were treated for only 24 hours, while the 
cell cycle assay used cells treated for 96 hours.  This timing of treatment may be the 
reason for the difference seen in the results of the two experiments.   
When compared to previous studies, our study used a much lower concentration 
of EL and ED because we wanted to preserve the health of the colonic cells, as well as 
stay as close to physiological levels of the lignans as possible.  To our knowledge, this is 
the first study that has demonstrated the effects of the flaxseed lignans EL and ED on a 
non-transformed cell line.  The compounds reduced growth, and increased apoptosis of 
YAMC cells.  There was also evidence of transcriptional regulation of apoptotic and cell 
cycle progression genes, leading us to believe that EL and ED have protective effects 
against the initiation and progression of colon cancer.  
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Future Research 
These studies were only the first steps to better understand the chemoprotective 
effects of flaxseed lignans in non-malignant colonocytes.  Further steps should be taken 
to better understand their mechanisms of action.  Next steps would include determining 
the compounds’ interaction with the main estrogen receptor in the colon epithelium, 
ERβ.  Additionally, studies should be conducted looking into the combinatory effects of 
EL and ED.  In vitro studies may also offer more insight into the chemoprotective roles. 
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NOMENCLATURE 
E2 Estradiol 
ERβ Estrogen receptor beta 
HRT Hormone replacement therapy  
SDG Secoisolariciresinoldiglucoside 
ED Enterodiol 
EL Enterolactone 
YAMC Young adult mouse colonocyte 
TA Transit Amplifying  
ER Estrogen receptor  
ERα Estrogen receptor alpha 
ERβ-KO Estrogen receptor beta knock out 
WT Wild type 
ACF Aberrant crypt foci  
AOM Azoxymethane  
GEN Genistein 
Trig Trigonelline 
DIM Diindolylmethane  
ALA Alpha-linolenic acid  
ω-3 FA Omega-3 fatty acids  
EPA Eicosapentaenoic acid 
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DHA Docosahexaenoic acid  
Seco  Secosisolariciresinol  
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